Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...
6hon MSN
Adds Kenvue comment. Kenvue (NYSE:KVUE) needs to focus on fixing its skin, health and beauty segments, Jeff Smith, founder ...
Starboard Value, the activist investor pushing for changes at Pfizer, unveiled its goals for another healthcare company — ...
In the assessment of 12-month price targets, analysts unveil insights for Kenvue, presenting an average target of $24.1, a ...
An exclusive Q&A with David Lickstein, Global Head of Packaging Innovation, Sustainability, and Experience, at Kenvue ...
Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty segment's lackluster ...
BofA raised the firm’s price target on Kenvue (KVUE) to $27 from $24 and keeps a Buy rating on the shares. Noting that The Wall Street ...
Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...
Kenvue, Inc. (KVUE – Research Report), the Technology sector company, was revisited by a Wall Street analyst yesterday. Analyst Anna ...
13h
Starboard Value LP (together with its affiliates, "Starboard" or "we"), today announced that Jeffrey Smith, the firm’s Chief Executive Officer and Chief Investment Officer, delivered a presentation at ...
By Svea Herbst-Bayliss (Reuters) -Hedge fund Starboard Value called consumer products company Kenvue a bargain and said its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback